Chroman and tetrahydroquinoline ureas as potent TRPV1 antagonists

被引：45

作者：

Schmidt, Robert G. ^{[1
]}

Bayburt, Erol K. ^{[1
]}

Latshaw, Steven P. ^{[1
]}

Koenig, John R. ^{[1
]}

Daanen, Jerome F. ^{[1
]}

McDonald, Heath A. ^{[1
]}

Bianchi, Bruce R. ^{[1
]}

Zhong, Chengmin ^{[1
]}

Joshi, Shailen ^{[1
]}

Honore, Prisca ^{[1
]}

Marsh, Kennan C. ^{[1
]}

Lee, Chih-Hung ^{[1
]}

Faltynek, Connie R. ^{[1
]}

Gomtsyan, Arthur ^{[1
]}

机构：

[1] Abbott Labs, Global Pharmaceut Res & Dev, Abbott Pk, IL 60064 USA

来源：

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2011年 / 21卷 / 05期

关键词：

TRPV1; antagonists; Pain; Chromanyl urea; Tetrahydroquinolinyl urea; VANILLOID RECEPTOR TRPV1; A-425619 1-ISOQUINOLIN-5-YL-3-(4-TRIFLUOROMETHYL-BENZYL)-UREA; PAIN;

D O I：

10.1016/j.bmcl.2011.01.056

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Novel chroman and tetrahydroquinoline ureas were synthesized and evaluated for their activity as TRPV1 antagonists. It was found that aryl substituents on the 7- or 8-position of both bicyclic scaffolds imparted the best in vitro potency at TRPV1. The most potent chroman ureas were assessed in chronic and acute pain models, and compounds with the ability to cross the blood-brain barrier were shown to be highly efficacious. The tetrahydroquinoline ureas were found to be potent CYP3A4 inhibitors, but replacement of bulky substituents at the nitrogen atom of the tetrahydroisoquinoline moiety with small groups such as methyl can minimize the inhibition. (C) 2011 Elsevier Ltd. All rights reserved.

引用

页码：1338 / 1341

页数：4

共 50 条

[21] TRPV1 antagonists as potential antitussive agents
McLeod, Robbie L.
Correll, Craig C.
Jia, Yanlin
Anthes, John C.
LUNG, 2008, 186 (Suppl 1) : S59 - S65
[22] TRPV1 antagonists: a survey of the patent literature
Kyle, Donald J.
Tafesse, Laykea
EXPERT OPINION ON THERAPEUTIC PATENTS, 2006, 16 (07) : 977 - 996
[23] Discovery of piperidine carboxamide TRPV1 antagonists
Cheung, Wing S.
Calvo, Raul R.
Tounge, Brett A.
Zhang, Sui-Po
Stone, Dennis R.
Brandt, Michael R.
Hutchinson, Tasha
Flores, Christopher M.
Player, Mark R.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2008, 18 (16) : 4569 - 4572
[24] TRPV1 antagonists: the challenges for therapeutic targeting
Khairatkar-Joshi, Neelima
Szallasi, Arpad
TRENDS IN MOLECULAR MEDICINE, 2009, 15 (01) : 14 - 22
[25] Synthesis of benzamide derivatives as TRPV1 antagonists
Shishido, Yuji
Jinno, Madoka
Ikeda, Takafumi
Ito, Fumitaka
Sudo, Masaki
Makita, Naoya
Ohta, Atsuko
Iki-Taki, Ayako
Ohmi, Takashi
Kanai, Yoshihito
Tamura, Tetsuya
Shimojo, Masato
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2008, 18 (03) : 1072 - 1078
[26] TRPV1 Antagonists as Potential Antitussive Agents
Robbie L. McLeod
Craig C. Correll
Yanlin Jia
John C. Anthes
Lung, 2008, 186 : 59 - 65
[27] Targeting TRPV1 by antagonists for pain relief
Trevisani, M.
NEUROPEPTIDES, 2009, 43 (05) : 451 - 451
[28] 4-(2-Pyridyl)piperazine-1-benzimidazoles as potent TRPV1 antagonists
Shao, B
Huang, JC
Sun, Q
Valenzano, KJ
Schmid, L
Nolan, S
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2005, 15 (03) : 719 - 723
[29] Repeated administration of vanilloid receptor TRPV1 antagonists attenuates hyperthermia elicited by TRPV1 blockade
Gavva, Narender R.
Bannon, Anthony W.
Hovland, David N., Jr.
Lehto, Sonya G.
Klionsky, Lana
Surapaneni, Sekhar
Immke, David C.
Henley, Charles
Arik, Leyla
Bak, Annette
Davis, James
Ernst, Nadia
Hever, Gal
Kuang, Rongzhen
Shi, Licheng
Tamir, Rami
Wang, Jue
Wang, Weiya
Zajic, Gary
Zhu, Dawn
Norman, Mark H.
Louis, Jean-Claude
Magal, Ella
Treanor, James J. S.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2007, 323 (01): : 128 - 137
[30] Structure-activity studies of a novel series of 5,6-fused heteroaromatic ureas as TRPV1 antagonists
Drizin, I
Gomtsyan, A
Bayburt, EK
Schmidt, RG
Zheng, GZ
Perrier, RJ
DiDomenico, S
Koenig, JR
Turner, SC
Jinkerson, TK
Brown, BS
Keddy, RG
McDonald, HA
Honore, P
Wismer, CT
Marsh, KC
Wetter, JM
Polakowski, JS
Segreti, JA
Jarvis, MF
Faltynek, CR
Lee, CH
BIOORGANIC & MEDICINAL CHEMISTRY, 2006, 14 (14) : 4740 - 4749

← 1 2 3 4 5 →